Resistance evolution against phage combinations depends on the timing and order of exposure by Wright, Rosanna Christina Taylor et al.
This is a repository copy of Resistance evolution against phage combinations depends on 
the timing and order of exposure.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/150225/
Version: Accepted Version
Article:
Wright, Rosanna Christina Taylor, Friman, Ville-Petri orcid.org/0000-0002-1592-157X, 
Smith, Margaret Caroline MacHin orcid.org/0000-0002-4150-0496 et al. (1 more author) 
(Accepted: 2019) Resistance evolution against phage combinations depends on the timing
and order of exposure. MBio. ISSN 2150-7511 (In Press) 
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 




Resistance evolution against phage combinations depends on the timing and order of 1 
exposure  2 
 3 
Running title: Resistance evolution against phage combinations   4 
 5 
Rosanna C.T. Wright1,2 #, Ville-Petri Friman1, Margaret C. M. Smith1, Michael A. Brockhurst2 6 
1. Department of Biology, University of York, York, YO10 5DD, UK 7 
2. Department of Animal and Plant Sciences, University of Sheffield, Sheffield, S10 2TN, UK 8 
 9 
# Author for correspondence: 10 
Dr Rosanna Wright 11 
Department of Animal and Plant Sciences  12 
University of Sheffield 13 
Western Bank 14 
Sheffield 15 
S10 2TN 16 
 17 
r.c.wright@sheffield.ac.uk  18 
Abstract 19 
Phage therapy is a promising alternative to chemotherapeutic antibiotics for the treatment of 20 
bacterial infections. However, despite recent clinical uses of combinations of phages to treat 21 
multidrug resistant infections, a mechanistic understanding of how bacteria evolve 22 
resistance against multiple phages is lacking, limiting our ability to deploy phage 23 
combinations optimally. Here we show, using Pseudomonas aeruginosa and pairs of phages 24 
targeting shared or distinct surface receptors, that the timing and order of phage exposure 25 
determines the strength, cost and mutational basis of resistance. Whereas sequential 26 
exposure allowed bacteria to acquire multiple resistance mutations effective against both 27 
phages, this evolutionary trajectory was prevented by simultaneous exposure, resulting in 28 
quantitatively weaker resistance. The order of phage exposure determined the fitness costs 29 
of sequential resistance, such that certain sequential orders imposed much higher fitness 30 
costs than the same phage pair in the reverse order. Together these data suggest that 31 
phage combinations can be optimised to limit the strength of evolved resistances whilst 32 
maximising their associated fitness costs to promote the long-term efficacy of phage 33 
therapy. 34 
 35 
Importance  36 
Globally rising rates of antibiotic resistance have renewed interest in phage therapy where 37 
combinations of phages have been successfully used to treat multidrug resistant infections. 38 
To optimise phage therapy, we first need to understand how bacteria evolve resistance 39 
against combinations of multiple phages. Here we use simple laboratory experiments and 40 
genome sequencing to show that the timing and order of phage exposure determine the 41 
strength, cost and mutational basis of resistance evolution in the opportunistic pathogen 42 
Pseudomonas aeruginosa. These findings suggest that phage combinations can be 43 
optimised to limit the emergence and persistence of resistance, thereby promoting the long-44 
term usefulness of phage therapy. 45 
  46 
Introduction 47 
Globally rising rates of resistance against all major classes of chemotherapeutic antibiotics 48 
has renewed interest in the therapeutic use of phages to treat bacterial infections (1, 2). 49 
However, like antibiotics, the evolution of bacterial resistance to phages could limit the long-50 
term sustainability of phage-based treatments (3). It is important therefore to understand the 51 
evolutionary processes determining the emergence of bacterial resistance against phage 52 
infection. Phages initiate infection by binding to molecules on the bacterial cell surface in a 53 
process called adsorption, therefore, a common form of resistance is to prevent adsorption 54 
by modifying the targeted surface molecule(s) that act as phage receptors (4±6). This can 55 
involve mutations affecting the regulation or biosynthesis of the surface molecule, leading to 56 
loss or altered structure of the receptor (6±8). Because the targeted surface molecules 57 
usually serve other functions ² for instance motility, cell membrane integrity or nutrient 58 
transport ² their alteration or loss is frequently associated with fitness costs, which can limit 59 
the success of resistant mutants in the absence of phages (9, 10). 60 
Resistance mutations against a single phage typically occur at high frequency and, due to 61 
phage-killing of susceptible genotypes, these resistance mutations will rapidly sweep 62 
through the bacterial population (8). Consequently, phage therapy usually involves the 63 
application of combinations of multiple phages, which is believed to limit the emergence of 64 
resistance in addition to targeting a wider range of bacterial genotypes (11, 12). There are 65 
two potential explanations for why phage combinations could limit the evolution of 66 
resistance: First, resistance to multiple phages may require multiple resistance mutations to 67 
arise in the same cell (13, 14), which is likely to occur with very low probability. Second, due 68 
to their associated fitness costs, the accumulation of multiple resistance mutations could 69 
lead to substantial loss of fitness if costs interact additively or synergistically (9, 10, 15, 16), 70 
reducing the ability of resistant cells to persist when faced with competition by non-resistant 71 
cells.  72 
The evolution of resistance against phage combinations could occur more readily if 73 
individual resistance mutations protected against more than one phage, a property called 74 
cross-resistance. Cross-resistance is most likely to be elicited between phages that target 75 
the same bacterial surface receptor, where resistance mutations causing modification or loss 76 
of the shared receptor prevents the adsorption of each of the phages  (7, 17, 18). 77 
Consequently, it is likely that successful phage combinations will tend to be those including 78 
phages that target multiple, distinct cell surface receptors because this will limit the potential 79 
for cross-resistance (14, 18). Moreover, although generalist cross-resistance mutations in 80 
global transcriptional regulators protecting against phages binding distinct receptors have 81 
been described, these occurred at lower frequency and incurred much higher costs than 82 
those affecting only a single receptor (7, 18).  83 
Application of multiple phages in combinations either simultaneously or sequentially could 84 
also affect the trajectory of resistance evolution (7, 17, 19). Previous experimental studies 85 
suggest that sequential exposure can be as effective as applying phages simultaneously, 86 
but it was not tested whether these treatments selected for qualitatively different resistance 87 
mutations (17). It is likely that resistances selected under sequential versus simultaneous 88 
phage exposure will differ: Sequential exposure provides more opportunity to accumulate 89 
multiple, specific resistance mutations, whereas simultaneous exposure may be more likely 90 
to select for a single, generalist cross-resistance mutation. Additionally, phage exposure 91 
prior to antibiotic treatment has been shown to improve bacterial killing more than either 92 
simultaneous treatment or the reverse order [i.e. antibiotic first; (20, 21)]. This suggests that 93 
the order in which antibacterial treatments are applied can have important effects on their 94 
efficacy, but the effect on the evolution of resistance to phage combinations remain unclear.  95 
Here, we test experimentally how the evolution, genetic basis and the cost of resistance 96 
against pairs of phages targeting either the same or different cell-surface receptors (LPS 97 
and Type IV pilus) in the Pseudomonas aeruginosa PAO1 strain depends on the timing and 98 
order effects when phages are applied in one-step (i.e. simultaneous exposure) or 99 
sequentially. We found that sequential exposure allowed accumulation of multiple phage-100 
specific resistances provided by mutations in cell surface receptor targets of phage 101 
adsorption without imposing any trade-offs in the strength of resistance. The order of phage 102 
exposure determined the fitness costs of sequential resistance, such that certain sequential 103 
orders imposed much higher fitness costs than the same phage pair in the reverse order. In 104 
contrast, simultaneous selection for phage resistances resulted in weaker resistance to both 105 
phages compared to the strength of sequentially acquired resistance with similar fitness 106 
costs. This suggests that phage combination treatments can be rationally designed to limit 107 
the strength of evolved resistances and to maximise fitness costs associated with 108 
resistance.  109 
Results 110 
Sequential resistance is rarely limited by a trade-off in resistance strength 111 
By exposing the bacterial host to different phages sequentially, we could assess how the 112 
strength of resistance to each phage was influenced by the order of phage exposure. For a 113 
pair of phages targeting lipopolysaccharide (LPS) receptors (PA10P2 and 14/1), we typically 114 
found that the first-step resistance mutation provided resistance to both phages of 115 
approximately equivalent strength (Figure 1A, Tukey test on ANOVA interaction: p>0.99 in 5 116 
out of 6 replicates). Hence, sequential selection for second-step resistance to the alternate 117 
LPS-associated phage did not tend to increase resistance against this second phage (Figure 118 
1A, Tukey test on ANOVA interaction: all p>0.1). Moreover, following the second-step of 119 
sequential selection we observed only minimal trade-offs in resistance to the first phage 120 
(maximum decrease ~15%). Nonetheless the order of exposure to phages appeared to have 121 
an effect on the occurrence of trade-offs: whereas no trade-off was observed in 14/1 122 
resistance following second-step sequential selection of PA10P2 resistance (Figure 1A, 123 
Tukey test on ANOVA interaction: all p>0.1), PA10P2 resistance was slightly reduced 124 
following second-step sequential selection of 14/1 resistance in 2 out of 3 replicates (Figure 125 
1A, Tukey test on ANOVA interaction: mean differences of -0.140 and -0.259, both p<0.001). 126 
In contrast, for pairs of phages that targeted different receptors, that is either the LPS or the 127 
Type-IV Pilus, the first-step resistance mutation rarely provided effective cross-resistance to 128 
the second-step phage. Whereas first-step resistance mutations against phage targeting 129 
LPS (PA10P2 or 14/1) provided a weak cross-resistance to the Type IV pilus-associated 130 
phage (PA5P2) in 2 out of 6 replicates (Figure 1B-C, Tukey test on ANOVA interactions: p = 131 
0.010 and 0.001), first-step resistance mutations against PA5P2 provided no cross-132 
resistance against the LPS-binding phages. This suggests that, unlike for the phage pairs 133 
that shared the LPS receptor, multiple resistance mutations were required to protect against 134 
sequential phage pairs that targeted different receptors (Figure 1B-C, Tukey test on ANOVA 135 
interaction: resistance to second phage after 1st step vs.  2nd step all p<0.001). However, the 136 
strength of the first-step resistance was rarely reduced following sequential selection for the 137 
second-step resistance (1 out of 12 replicates). Indeed, we observed increases in the 138 
strength of the first-step resistance in half of the replicates following acquisition of the 139 
second-step resistance mutation (Figure 1B/C, Tukey test on ANOVA interaction: all 140 
p<0.001). This implies that when phages target different receptors, sequential phage 141 
selection leads to additive resistances that rarely impose trade-offs in the strength of 142 
resistance to phages that adsorb to different cell-surface receptors.  143 
Simultaneous phage selection results in weak resistance to both phages 144 
To determine if equivalent resistances against pairs of phages could be achieved in one-145 
step rather than two sequential steps, we also selected resistant mutants against each 146 
phage pair simultaneously. Simultaneous selection by the phage pair targeting the LPS 147 
generally resulted in weaker resistance compared to the first-step and second-step 148 
resistance mutations observed during sequential selection with the same phages (Figure 1A; 149 
Tukey test on ANOVA interaction, simultaneous weaker than 1st-step sequential in 5/6 150 
replicates p<0.05; simultaneous weaker than 2nd-step sequential in 5/6 replicates, p<0.05). 151 
Similarly, simultaneous selection for resistance against the phage pairs targeting different 152 
receptors consistently resulted in weaker resistance to both phages compared to sequential 153 
resistance selection (Figure 1B-C; Tukey test on ANOVA interactions: PA5P2 resistance - all 154 
replicates weaker with p<0.005; PA10P2 resistance - 3/6 replicates weaker with p<0.05; 155 
14/1 resistance - all replicates weaker with p<0.05). Together, these results indicate that 156 
simultaneous exposure to multiple phages can reduce the strength of evolved resistance, 157 
even when the phage strains target the same receptor and promote reciprocal cross-158 
resistance.  159 
Cost of resistance against multiple phages is determined by the order of applied phages 160 
The emergence of highly resistant bacteria could be limited if strong resistance against 161 
multiple phages arising from sequential acquisition of resistance mutations was associated 162 
with higher costs (i.e. lower relative fitness). Thus, we next compared the growth kinetics of 163 
the resistant mutants relative to the phage-susceptible ancestral bacterial genotypes. 164 
Sequential resistance was more costly than equivalent simultaneous resistance in nearly 165 
half of replicates, however we also observed that sequential resistance could impose equal 166 
or lower costs than equivalent simultaneous resistance (Figure 2; Tukey test on ANOVA 167 
interactions: sequential resistance more costly in 6/13 replicates p<0.05; sequential less 168 
costly in 2/13 replicates p<0.05; no significant difference in 5/13 replicates). This suggests 169 
that strong resistance against multiple phages can often be acquired sequentially without 170 
additional cost compared to weaker resistance acquired under simultaneous phage 171 
exposure. Nonetheless, order effects were important in determining the cost of resistance for 172 
some sequential resistances. When the first-step resistance was against a Type IV pilus 173 
binding phage followed by second-step resistance against a LPS-binding phage, we 174 
observed significant reductions in relative fitness following the second-step in half of the 175 
replicates (Figure 2B-C; Tukey test on ANOVA interaction: 3/6 replicates p<0.05), whereas 176 
no significant change in fitness cost was observed with the opposite order of phage selection 177 
(i.e. exposure to first LPS-binding then type-IV pilus-binding phage). This suggests that the 178 
cost of resistance is mutation-specific, and fitness can be determined by order effects 179 
indicative of epistatic interactions between specific resistance mutations.     180 
 181 
The genetic basis of phage resistance after sequential versus simultaneous phage selection 182 
To assess how the genetic basis of resistance varied between phage selection treatments, 183 
we sequenced the whole genomes of three resistant mutants exposed to each pairwise 184 
combination of the phages PA5P2, PA10P2 and 14/1 under both sequential and 185 
simultaneous selection regimes. Whereas single-phage resistance (i.e. first-step of 186 
sequential selection) promoted acquisition of single mutations, selection of multiple phage-187 
resistances was generally provided by multiple resistance mutations in both simultaneous 188 
and sequential selection regimes (Tukey test on ANOVA interaction: 2nd-step sequential vs. 189 
1st-step sequential, diff=1.20, p<0.0001; simultaneous vs. 1st-step sequential, diff=1.18, 190 
p<0.001; simultaneous vs. 2nd-step sequential, diff=-0.018, p=0.997). 191 
For sequential resistance, we found that the first step resistance against all phages relied 192 
upon single variants in receptor-specific genes (Figure 3A; Table S4.1), with only one case 193 
of a secondary mutation which was likely due to hitch-hiking. Most mutations conferring first-194 
step resistance to LPS-binding phages (PA10P2 and 14/1) targeted the wzy gene, which 195 
encodes a polymerase involved in synthesis of the LPS B-band O-antigen (Table S4.1). All 196 
first-step resistance mutants selected using the type-IV pilus binding phage PA5P2 carried a 197 
single mutation affecting Type-IV pilus-associated genes (Figure,3A; Table S4.1), including 198 
pilB (encoding a motor protein controlling pilus extension), pilN (encoding a product involved 199 
in pilus assembly), and pilR (encoding part of a two-component system regulating pilin 200 
production).  201 
Sequential resistance against combinations of phages targeting different receptors required 202 
a combination of two mutations, each affecting a distinct receptor-specific target (Figure 3B; 203 
Table S4.1). Second-step resistance against the type-IV pilus binding phage PA5P2 204 
required mutations targeting genes involved in pilus motility (pilT and pilU), extension and 205 
retraction (pilB and pilY1 respectively), and structural pilins (pilE) (note however that for two 206 
replicates we were unable to identify the first-step mutations and therefore these sequences 207 
were discarded). Second-step resistance against an LPS-binding phage (PA10P2 or 14/1) 208 
commonly required secondary mutations in wzy, the same gene that provided first-step 209 
resistance against these phages. Interestingly, however, in two out of three replicates of 210 
sequential selection with PA5P2 followed by 14/1, we observed second-step mutations in a 211 
distinct target, galU, a uridylyltransferase involved in LPS biosynthesis. Additional mutations 212 
in non-receptor-specific genes were found in 3 out of 6 replicates where resistance to the 213 
Type IV pilus-associated phage was followed by sequential LPS-associated resistance, 214 
whilst no additional mutations were found in the reverse treatment order (i.e. LPS followed 215 
by Type IV pilus) (Figure 3B; Table S4.1). Taken together these genetic data confirm that 216 
trade-offs in resistance strength between combinations of phages which bind different 217 
receptors were uncommon when resistance was acquired sequentially because multiple 218 
receptor-specific mutations were acquired providing additive resistance.   219 
In the case of sequential selection by pairs of phages targeting the same receptor, we 220 
observed order effects for the number and targets of resistance mutations. Only one 221 
mutation was detected per replicate following sequential selection with 14/1 followed by 222 
PA10P2, whereas for the reverse order we observed additional mutations in the second-step 223 
mutants (Figure 3B; Table S4.1). For two replicates, we observed mutations in a gene of 224 
unknown function, PA0429, whilst the third replicate gained a second LPS-associated 225 
mutation (wapH, predicted glycosyl transferase; Table S4.1). It is unclear why parallel 226 
mutations in PA0429 would be selected because they provided no increase in resistance to 227 
14/1 (in fact the first step resistance mutations in these replicates already provided strong 228 
cross-resistance to 14/1; Figure 1), nor any reduction of the associated fitness costs (Figure 229 
4; Tukey test on ANOVA: wzy vs. wzy+PA0429 p=0.978). By contrast, the wapH mutation 230 
did improve 14/1 resistance; here the first-step resistance mutation in the LPS biosynthesis 231 
gene rml, encoding a thymidylyltransferase, provided weak cross-resistance to 14/1 (Tukey 232 
test on ANOVA: strength of focal resistance vs. cross-resistance, diff = -0.463, p<0.0001), 233 
and furthermore, gaining the second-step resistance mutation was not associated with any 234 
increase in fitness costs (Figure 4; Tukey test on ANOVA: rmlA vs. rmlA+wapH p=1).  235 
In contrast, accumulation of multiple receptor-specific resistance mutations was never 236 
observed when phage pairs that targeted Type IV pilus or LPS receptors were applied 237 
simultaneously (Figure 3C). Half of the resistant mutants resulting from simultaneous 238 
exposure to phage pairs with different receptor targets carried mutations in LPS-associated 239 
genes without any additional Type IV pilus-specific mutations (Figure 3C). Surprisingly, we 240 
were unable to identify any mutations in 2 out of 6 replicates, suggesting that these clones 241 
had either displayed phenotypic resistance or had subsequently undergone a reversion 242 
mutation to restore phage sensitivity. In two resistance mutants, we observed duplication of 243 
the same two genes (approx. 1Mb apart) both linked with DNA recombination: one encoding 244 
a single-strand DNA binding protein (ssb) and the other a putative exonuclease (PA3263). 245 
However, the relationship between the gene duplication and phage resistance is currently 246 
unclear.  247 
Despite LPS binding phages promoting strong reciprocal cross-resistance, 2 out of 3 248 
resistance mutants selected against PA10P2 and 14/1 simultaneously had secondary 249 
mutations in non-LPS genes in addition to LPS-associated mutations. One mutant had a 250 
large deletion of approximately 250 kbp (around 4% of the whole genome), affecting over 251 
200 genes including galU, the LPS biosynthesis gene that was also mutated under 252 
sequential selection against PA5P2 and 14/1 (Figure 3C). This indicates that whilst PA10P2 253 
and 14/1 both adsorb to the LPS, they probably target different sites, such that the strength 254 
of cross-resistance depends on specific effects of mutations on the LPS structure. 255 
Fitness costs associated with specific resistance mutations 256 
Across all genome sequenced resistant mutants, those which had acquired multiple 257 
resistance mutations were less fit than those with only single resistance mutations (t-test, 258 
t93.2=4.63, p<0.0005). Fitness costs were often additive for combinations of LPS and Type-IV 259 
pilus mutations, with pairs of resistance mutations imposing greater costs than single 260 
resistance mutations on their own (Figure 4). Second-step mutations in the LPS-associated 261 
gene galU increased fitness costs in combination with first-step mutations in Type IV pilus 262 
genes (Figure 4; Tukey test on ANOVA: pilN vs. pilN+galU p<0.0001; pilR vs. pilR+galU 263 
p<0.0001), but this was not the case for wzy which imposed no additional cost (Figure 4; 264 
Tukey test on ANOVA: pilR vs. pilR+wzy p=0.826). Similarly, for sequential resistance 265 
selected against the pair of LPS-binding phages, secondary mutations in both LPS and non-266 
LPS targets were effectively cost-free (Figure 4; Tukey test on ANOVA: wzy vs. 267 
wzy+PA0429 p=0.978; rmlA vs. rmlA+wapH p=1.00). Whilst we were unable to calculate 268 
epistatic effects for most double mutants, as different loci were targeted in respective stages 269 
of sequential selection or multiple mutations were acquired concurrently, these results 270 
indicate that fitness costs of sequential resistance against multiple phages are likely to 271 
depend on epistatic interactions between the specific multiple resistance mutations.  272 
Discussion 273 
We compared the evolutionary trajectory of phage resistance selected sequentially versus 274 
simultaneously against pairs of phages targeting either the same, or different cell-surface 275 
receptors required for adsorption and infection of the bacterial cell. Sequential resistance to 276 
phage combinations targeting different receptors was acquired by accumulation of multiple 277 
receptor-specific mutations which promoted strong additive resistance to both phage strains 278 
without trade-offs in the strength of resistance to each phage. In comparison, simultaneous 279 
exposure to multiple phages resulted in weaker resistance to both phages, through either 280 
single receptor-specific mutations, or other major genetic variations (i.e. deletion and 281 
duplication events) affecting a larger number of genes. Furthermore, although sequentially-282 
acquired resistance was generally much stronger, it often imposed no greater cost to host 283 
fitness than the corresponding (weaker) simultaneous resistance. This suggests that 284 
simultaneous phage exposure imposes far greater constraint on resistance evolution than 285 
sequential exposure, leading to weaker resistance at the same fitness cost, which would be 286 
highly beneficial when applying phages in a therapeutic context.  287 
Phages targeting the same receptor (LPS) provided strong cross-resistance to one another, 288 
such that the first-step of sequential resistance provided equally strong resistance to both 289 
LPS±binding phages through acquisition of a single mutation affecting LPS biosynthesis, 290 
irrespective of the focal LPS-binding phage used to select resistance. We therefore 291 
expected that simultaneous and second-step sequential selection against two-LPS binding 292 
phages would be equivalent to the first step of sequential selection. Consistent with this, 293 
under sequential selection resistance to both LPS-binding phages was provided by single 294 
mutations in LPS biosynthesis associated genes, and although second-step mutations were 295 
observed upon second-step exposure to 14/1 (in PA0429), this mutation neither affected 296 
resistance or fitness. By contrast, under simultaneous exposure, multiple resistance 297 
mutations were observed in two out of three replicates, one of which was a large deletion 298 
affecting approximately 4% of the host genome. This suggests that even when phages 299 
target the same receptor, subtle differences in their target sites may make it harder to resist 300 
both phages simultaneously through a single mutation, even-though single mutations 301 
providing resistance to both phages are available when encountered individually.  302 
For combinations of phages targeting different receptors, we found that the order of 303 
exposure to phages could determine the trajectory of resistance evolution, and its 304 
associated fitness costs. Sequential exposure to an LPS-binding phage following a Type IV 305 
pilus-binding phage decreased the relative fitness of the host, whereas there was no 306 
significant change in the cost between the two stages of sequential exposure in the opposite 307 
direction (i.e. Type IV pilus-binding phage after LPS-binding phage). Similar Type IV pilus 308 
mutations were selected in both sequential treatment orders, commonly affecting gene 309 
products involved in pilus-dependent motility [e.g. pilB, pilT and pilU encode motor proteins 310 
and pilY1 encodes an anti-retraction factor; (22, 23)]. The LPS biosynthesis gene wzy (24) 311 
was targeted in both sequential treatments, but imposed only modest increases in fitness 312 
cost, whereas mutations in galU, a uridylyltransferase also involved in LPS biosynthesis 313 
(25), were selected twice under selection with the LPS-binding phage 14/1 following initial 314 
selection against the Type IV pilus-binding phage PA5P2 and caused severe decreases in 315 
bacterial fitness. Whereas mutations in wzy often affect only the B-band of LPS (13, 26), 316 
galU mutations may cause broader structural changes, affecting both the LPS core and A-317 
band (27), which may explain their more detrimental effect on bacterial fitness.  Additionally, 318 
it is possible that some primary mutations limit the acquisition of secondary mutations, for 319 
example, in second-step clones exposed to Type IV pilus-binding phage PA5P2 we were 320 
unable to detect the LPS-associated mutations in rmlA and ssg present in the first-step 321 
sequenced clone  (28, 29). Strong negative epistatic interactions between receptor-specific 322 
resistant mutations could limit or prevent the survival of bacteria carrying both mutations 323 
(although it should be noted that our experimental design did not permit direct measurement 324 
of epistatic interactions). Taken together these data suggest that sequential selection with 325 
Type IV pilus-binding phage followed by LPS-binding phage may both decrease the 326 
likelihood of multiple phage resistance genotypes arising and impose substantial fitness 327 
costs upon those cells that do evolve resistance, which may be sufficient to allow eradication 328 
RI WKH LQIHFWLRQ E\ DQWLELRWLF WUHDWPHQW RU HYHQ E\ WKH SDWLHQW¶V RZQ LPPXQH V\VWHP329 
Rational design of sequential phage treatments to optimise these types of order effects 330 
could direct the trajectory of resistance evolution, allowing high fitness costs to be promoted 331 
and limiting fixation of certain resistance mutations.  332 
Compared to sequential selection of resistance, simultaneous exposure promoted 333 
acquisition of weaker resistance. Whereas sequential resistances in different receptor 334 
targets provided additive resistance, simultaneous exposure often led to single receptor-335 
specific mutations which provided relatively weak resistance to only one of the phages, or 336 
more complex mutational effects (e.g. duplication and deletion events) targeting many genes 337 
including some not known to be associated with LPS or Type IV pilus. Although large 338 
deletions have been previously reported to provide phage resistance in vitro (30, 31), the 339 
loss of a large number of genes is likely to have major pleiotropic effects in more complex 340 
environments where bacteria must respond to various environmental stressors (32, 33) and 341 
may be influenced by the resident microflora (34). Additionally, single mutations which do 342 
not provide resistance to all phages present in the cocktail may not be sufficient to allow 343 
survival under sustained phage pressure (e.g. if phage propagate in vivo). Overall, this 344 
suggests that there are fewer mutational routes allowing bacteria to survive in the presence 345 
of multiple phages simultaneously.  346 
Bacterial phenotypic responses to stressors may also explain why we were unable to identify 347 
resistance mutations in some hosts exposed simultaneously to multiple phage strains. 348 
Stochastic environmental changes which affect bacterial lifestyle traits can hinder phage 349 
infection in numerous ways and create heterogeneity in host phenotypes within a population 350 
(35): changes in temperature can affect the rigidity of the host cell membrane preventing 351 
phage infection (36), and nutrient variability can reduce expression of phage receptors (37±352 
39). Changes in receptor expression levels could potentially limit phage adsorption 353 
sufficiently to enable survival of the host under simultaneous selection with multiple phage 354 
strains without leaving a genetic trace (40). Such resistances may be incidental to phage 355 
infection, or induced by phage products in the environment and/or products of cellular lysis, 356 
and may be considered as a phenotypic phage resistance (35, 37). Alternatively, survival in 357 
the presence of multiple phages may require such costly resistance mutations that as soon 358 
as phage selection pressures are relieved reversion mutants restoring the original genotype 359 
rapidly outcompete the resistant genotype as the colony grows (41, 42). Although reversion 360 
is often much less likely than acquisition of compensatory mutations (43), we saw little 361 
evidence of compensatory mutations in our experiment, however, we did observe secondary 362 
mutations in genes of unknown function which arose concurrently with receptor-specific 363 
mutations suggesting that compensation may be occurring. Ecological factors which 364 
influence population densities, adaption responses and stress-mediated effects may 365 
influence both the accumulation and persistence of phage resistance mutations, by 366 
potentially promoting phenotypic resistance or rapid compensation, therefore a better 367 
understanding of these interactions is required to design more durable phage therapeutics.  368 
There are several caveats with respect to the wider implications of this work. First, we were 369 
largely unable to isolate resistant mutants against the pilus-binding phage PT7, suggesting 370 
that strong phage identity effects may overwhelm the effect of phage order and timing of 371 
exposure. It is possible that resistance mutations against PT7 are very rare or incur such 372 
high fitness costs that resistant mutants do not survive. Second, we only consider here the 373 
emergence of spontaneous resistance mutations during short <48h incubations; different 374 
patterns of resistance could emerge over longer time periods offering more opportunity for a 375 
wider range of mutations to arise, including compensatory mutations to ameliorate fitness 376 
costs. Third, we used only a limited number of phages strains targeting just 2 distinct 377 
bacterial receptors. To determine whether the principles of resistance emergence observed 378 
here can be generalised, future work will be needed to test a wider range of genetic and 379 
functional diversity of phages, including those binding a wider range of receptors, and to 380 
determine the contribution of other modalities of phage resistance in the bacterial hosts, for 381 
instance CRISPR-Cas systems.  382 
In conclusion, we found that the fitness cost of multi-phage resistance could be maximised 383 
under specific orders of phage exposure by selecting for Type IV pilus-associated resistance 384 
mutants followed by LPS-associated resistance mutants. As fitness costs are potentially 385 
exacerbated in vivo, due to more intense competition for resources and the requirement of 386 
expression of a broader range of traits (44, 45), maximising fitness costs associated with 387 
phage resistance could reduce the long-term success of resistant mutants. On the other 388 
hand, simultaneous exposure to multiple phage strains often imposed similar costs to 389 
sequential treatments but for weaker resistance against the phage combination. Due to the 390 
potential for phages to propagate and evolve to overcome bacterial resistance during 391 
treatment by replicating on susceptible bacteria, limiting the strength of evolved resistance 392 
may be just as beneficial as maximising host fitness costs. Further experiments are 393 
warranted to determine the relative importance of these effects in vivo, as more complex 394 
environmental pressures may exacerbate fitness costs and buffer differences in resistance 395 
strength. However, these results highlight that the rational design of phage cocktails to target 396 
multiple bacterial targets can limit the evolution of strong phage-resistance and determine 397 
the fitness cost of evolved resistance. 398 
Materials and Methods 399 
Strains and culture conditions 400 
Bacterial cultures of P. aeruginosa 3$2 ZHUH JURZQ LQ .LQJ¶V PHGLD % .% DV PO401 
volumes in a 30ml glass microcosm with loose plastic fitting lids, and incubated at 37qC, 402 
shaken (180rpm). Four genetically distinct phage strains with characterised adsorption 403 
targets (18), were used to select phage resistance: PA5P2 and PT7 (Type IV pilus-binding 404 
phage), PA10P2 and 14/1 (LPS-binding phage). Phage cultures were prepared directly from 405 
frozen glycerol stocks, added to approximately 107 cells ml-1 of ancestral PAO1 from 406 
overnight culture and incubated overnight at 37qC, shaken (180rpm). Phage stocks were 407 
purified by filtration to remove bacteria (0.22Pm), and stored at 4qC. 408 
 409 
Selection of spontaneous phage-resistant mutants 410 
We used a modified fluctuation test (46) to select spontaneous phage-resistant mutants 411 
against all pairwise phage combinations, under both simultaneous and sequential selection. 412 
Three independent bacterial colonies were selected by streaking out the ancestral bacteria 413 
directly from glycerol stock onto KB agar (incubated overnight at 37qC); colonies were 414 
inoculated into 6ml KB and incubated at 37qC (shaken) for 8h, then used to found 10 415 
subpopulations by diluting each culture 10-fold into 10 wells of a 96 well microplate 416 
containing KB media to a final volume of 200Pl. Samples of these initial bacterial cultures 417 
were also frozen (20% glycerol, -80qC) to be used for replicates, and assigned the names 418 
PAO1_FT1, PAO1_FT2, PAO1_FT3.  419 
For each ancestral replicate, we selected phage resistance against each of the 4 individual 420 
phage strains independently (1st step of sequential selection) and simultaneously against 421 
each possible phage pair (i.e. 6 different pairwise combinations) by exposing each of the 10 422 
bacterial subpopulations to a different phage treatment. Bacterial subpopulations were 423 
diluted 100-fold into 600ul of phage stock solution (300ul of each phage for simultaneous 424 
selection) in deep-well 96 well plates, giving a multiplicity of infection of ~100 phage per 425 
bacteria at a density of ~107 bacterial cells per ml, then plated out in 60ul volumes onto KB 426 
agar. For combinations with low expected mutation frequency, the complete mixture was 427 
plated (i.e. all 600ul in 60ul volumes). Following incubation at 37qC for 24h, single colonies 428 
were picked from each plate and re-streaked onto KB agar to remove phage particles and 429 
incubated overnight. If no colonies were present, the same plates were incubated for a 430 
further 24h at 37qC to allow slow-growing mutants time to produce colonies, which were then 431 
selected and re-streaked as before. Single colonies were selected from streak plates and 432 
grown overnight in 6ml KB, before glycerol stocks were prepared (20% glycerol, stored at -433 
80qC) and characterised for phage-resistance by cross-streaking against pure stocks of 434 
each phage strain on KB agar. Any phage treatments for which no bacterial colonies could 435 
be selected, or where selected colonies lacked any phage resistance, the whole selection 436 
process was repeated using the same initial ancestral clone, inoculated directly from the 437 
glycerol stock to produce bacterial subpopulations. One clone per ancestral replicate was 438 
then chosen for further characterisation (i.e. resistance strength, fitness costs and sequence 439 
analysis), based on initial cross-streaking results. This produced a total of 12 resistant 440 
mutants selected against single phage strains (1st step sequential selection ± 3 ancestral 441 
replicates x 4 phage strains), and 18 resistant mutants selected against two phages 442 
simultaneously (i.e. 3 ancestral replicates x 6 pairwise phage combinations).  443 
To complete sequential selection, we next exposed resistant bacteria selected against 444 
individual phages (i.e. 1st step sequential selection) to each additional phage strain (2nd step 445 
sequential selection). Clones selected in the first step of sequential selection were 446 
inoculated directly from glycerol stocks in to 6ml KB and grown for 8h at 37qC, then diluted 447 
10-fold into 3 wells of a 96 well plate to found 3 subpopulations per clone, which were used 448 
to select 2nd step sequential resistance against each of the other phage strains using the 449 
same protocol as above. This produced a further 36 resistant mutants (3 ancestral replicates 450 
x 4 1st-step phages x 3 2nd step phages). As before, any clones lacking phage-resistance, or 451 
phage treatments producing no viable colonies, were repeated. This was mainly an issue for 452 
combinations including phages PA5P2 and PT7 (both Type IV pilus binding): up to 75% of 453 
populations yielded no resistant muWDQWVIXUWKHUFRPSRXQGHGE\DODFNRI µWUXH¶UHVLVWDQFH454 
in the selected 455 
colonies (up to 90% of selected colonies lacking quantitative resistance when selected 456 
against combinations including PT7 or PA5P2). Selection treatments including phage PT7 457 
had extremely low mutation frequencies (e.g. 1 colony on >100 agar plates) and a high 458 
error-rate both due to lack of phage-resistance in selected PAO1 colonies and bacterial 459 
contamination (non-PAO1 colonies; this does not affect other treatments as all resistant 460 
mutants presented were confirmed to be PAO1 using whole genome sequencing). This 461 
indicates that true PT7 resistance is very difficult to acquire in combination with other phage 462 
strains, and therefore treatments containing phage PT7 (under both sequential and 463 
simultaneous selection) were later discarded.  464 
Quantitative resistance assays 465 
To determine the strength of resistance provided by mutations selected at each stage of 466 
sequential selection, and by simultaneous exposure to multiple phages, all spontaneous 467 
resistant mutants were assayed against all ancestral phage strains. Resistance assays were 468 
performed in 96 well microplates in KB media added to a final volume of 150Pl. A ratio of 469 
approximately 10 phage per bacteria was used, giving densities of ~107 bacterial cells and 470 
~108 phage particles per ml (i.e. multiplicity of infection of ~10). The strength of resistance 471 
was measured as Relative Bacterial Growth (RBG) in the presence of phage relative to in 472 
the absence of phage (Eq.1, where t denotes time and Abs for absorbance at 600 nm; 473 
Poullain et al., 2008), such that a value of 1 indicates complete resistance (i.e. equal growth 474 
in the presence and absence of phage). For resistant mutants with high fitness costs which 475 
result in slow growth (e.g. where the lag time may be up to 8h), a 48h endpoint was used to 476 
calculate RBG instead of 8h.    477 
For phage i, bacteria j: 478 
ܴܤܩ௜௝ ൌ  ሾ஺௕௦లబబሺ௧ୀ଼௛ሻି஺௕௦లబబሺ௧ୀ଴௛ሻሿ೔ೕሾ஺௕௦లబబሺ௧ୀ଼௛ሻି஺௕௦లబబሺ௧ୀ଴௛ሻሿ೎೚೙೟ೝ೚೗ೕ(1) 479 
Relative fitness of phage-resistant mutants 480 
To assess the fitness costs imposed by different resistance mutations, we compared the 481 
growth of all resistant mutants to the ancestral PAO1 strain in the absence of phage. 482 
Bacterial cultures were inoculated into 150Pl KB media in 96 well microtitre plates directly 483 
from glycerol stocks and incubated at 37qC with a shaking cycle every 30mins when optical 484 
density was measured as absorbance at 600nm, for a total of 48h to produce a growth 485 
curve. Four growth parameters were calculated from each growth curve to fully characterise 486 
changes in bacterial growth: the lag time before exponential growth begins, the maximum 487 
growth rate, the integral of the growth curve, and the maximum optical density reached (i.e. 488 
yield) (18). To calculate relative fitness, we used the maximum growth rate as it corelated 489 
well with both the integral and maximum optical density (Supplementary Figure 1). The 490 
Maximum growth rate for each resistant mutant was divided by the mean ancestral 491 
maximum growth rate (with replicates matched within plates) to give relative fitness. A 492 
relative fitness of 1 indicates equal fitness with the ancestral strain, indicating that any 493 
resistance mutations present impose no fitness costs.  494 
Sequence analysis 495 
All spontaneous phage-resistant mutants were sequenced using the Illumina MiSeq platform 496 
(performed by MicrobesNG, University of Birmingham), and resistance mutations were 497 
detected using the following bioinformatics analysis: short-reads were aligned to an 498 
annotated PAO1 reference using Burrows-Wheeler Aligner (48), GATK Haplotype Caller 499 
(49) was used to identify SNPs and small indel variants, followed by annotation of gene 500 
information using SNPeff (50). Called variants were quality filtered by coverage (>20 reads 501 
per bp), and frequency of alternative allele (>80% of reads match alternative). Variants 502 
which occurred in all replicates were discarded as they represent differences between the 503 
annotated PAO1 reference genome (accession ID AE004091) and the ancestral genotype 504 
used in our experiments. All replicates evolved from ancestral clone PAO1_FT3 contained 505 
the same SNP in gene PA3676; therefore, because this mutation must have arisen prior to 506 
the fluctuation test (i.e. when individual ancestral colonies were selected) and imposed no 507 
detectable fitness effect, it was ignored in subsequent analyses. Larger genetic variations, 508 
including deletions over 100bp and duplication events, were identified by analysing changes 509 
in coverage depth in R (51), and all variants were verified visually using an alignment viewer 510 
(52). Variation in the number of mutations acquired under different selection regimes was 511 
assessed using an ANOVA with post-hoc Tukey tests, including a main effect of ancestral 512 
replicate. The relative fitness of mutants carrying either single or double resistance 513 
mutations were compared using post-hoc Tukey tests following an ANOVA.  514 
Statistical analysis 515 
The effect of selection regime (i.e. simultaneous versus each stage of sequential selection) 516 
on both resistance and relative fitness data were analysed using multiple ANOVAs (blocked 517 
by ancestral genotype and phage pair) followed by post-hoc Tukey tests. Multiple pairwise 518 
comparisons reported in the results section were taken from the outputs of these models. 519 
Blocking by ancestral genotype and phage pair identity avoided violation of independence 520 
assumptions, i.e., so that differences between the ancestral genotypes (i.e. PAO1_FT3 has 521 
1 SNP not present in PAO1_FT1 or FT2) and resistance mutations from step 1 of sequential 522 
selection are accounted for in these analyses. In addition, the time at which RBG was 523 
calculated (i.e. if 48h rather than 8h for slow-growing resistant mutants with high fitness 524 
costs), was included as a random effect.  525 
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 683 
Figure legends 684 
Figure 1. Trade-offs in the strength of resistance to each selection phage 685 
Strength of resistance, measured as reduction in bacterial growth (RBG r se), such that 1 686 
indicates equal growth in the presence and absence of phage. Selection treatment for focal 687 
resistance is indicated by colour (see individual keys). Background shading indicates the 688 
mean resistance strength for the first step in sequential resistance treatments to highlight 689 
changes in resistance to the first-step phage in the second step of sequential selection 690 
treatments.  691 
 692 
Figure 2. Relative fitness of resistant mutants is determined by selection regime 693 
Fitness is measured as the maximum growth rate achieved during a 48h growth period and 694 
given relative to that of the ancestral genotype; a value above 1 (light grey background) 695 
indicates lack of fitness costs associated with resistance mutation(s). Data points indicate 696 
the mean of 3 technical replicates (rse) measured for each set of biological replicates (plot 697 
headings indicate ancestral genotype used in the fluctuation test).  Selection treatment for 698 
focal resistances is indicated by colour (see individual keys). The mean relative fitness of 699 
simultaneous selection treatments is shown as a dashed purple line, with light purple 700 
shading to indicate standard error. Missing data indicates that no resistant mutants were 701 
recovered for that replicate treatment. 702 
 703 
Figure 3. Treatment regimes determine the frequency and type of resistance 704 
mutations selected 705 
Total number of identified mutations per resistant mutant across phage selection treatments 706 
(plot headings) under A) single B) sequential or C) simultaneous selection. Colours indicate 707 
category of mutational target (see key). 708 
 709 
Figure 4. Contrasting fitness costs resulting from specific combinations of single and 710 
double mutations 711 
Fitness relative to the ancestor, where a value of 1 indicates equal fitness and below 1 712 
indicates a fitness cost associated with labelled single (left panel) or double (right panel) 713 
mutations. The dashed line indicates predicted additive cost of two mutations affecting 714 
different receptors, given as the sum of the mean cost of individual receptor-specific 715 
mutations (grey band; single LPS mutations RF = 0.886, single Type IV pilus specific 716 
mutations RF = 0.880). 717 
 718 
Supplementary Figure 1.  Multiple pairwise comparisons of growth curve metrics.  719 
The diagonal shows the distribution of each measurement extracted from 48h growth curves 720 
of all phage-resistant mutants and phage-susceptible ancestral controls: Maximum growth 721 
rate as change in absorbance through time (OD600/h); Lag time before exponential phage 722 
(h); Yield (maximum OD600); and Integral of the growth curve (OD600.h). Scatter plots in 723 
the lower quadrant give pairwise correlations with respective R2 values in the top quadrant.  724 
 725 
Supplementary Table 1. Identity and function of genes where mutations were 726 
identified 727 
 728 
